Every Form 4 that Argan, Inc (AGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGX filings page.
ARGAN INC (symbol: AGX) is the issuer of record for a Form 4 filing submitted to the SEC. Collins Charles Edwin IV reported acquisition or exercise transactions in this Form 4 filing.
ARGAN INC (AGX) reported that Charles Edwin Collins IV, Chief Executive Officer of subsidiary Gemma, received a grant of 3,506 Time-Based Restricted Stock Units (TRSUs) on September 9, 2026. These TRSUs represent potential shares of common stock and will vest fully on September 9, 2029, increasing his reported direct holdings of these units to 6,404.
Argan Inc. director Jeffrey John Ronald Jr. reported selling 5,716 shares of common stock on July 31, 2026 at an average price of $579.64 per share in open-market transactions. After this sale, he holds 2,533 shares directly and 8,000 shares indirectly through a John R. Jeffrey IRA.
ARGAN INC director Jeffrey John Ronald Jr. reported exercising stock options to acquire a total of 6,000 shares of common stock on June 30, 2026. He exercised 5,000 options granted on December 16, 2022 at $35.72 per share and 1,000 options granted on December 14, 2023 at $43.70 per share, both using the net settle method.
Following these exercises, his direct ownership in ARGAN common stock increased to 8,249 shares. In addition, 8,000 shares are held indirectly through an account described as "John R. Jeffrey, IRA." The filing shows no open-market purchases or sales; all reported activity reflects option exercises.
ARGAN INC director William F. Griffin Jr. reported two open-market sales of the company’s common stock held indirectly through the “William F Griffin Jr GRAT II dtd Oct 6, 2025.” On June 18, 2026, the GRAT sold 30,000 shares at an average price of $725.85 per share. On June 22, 2026, it sold another 20,000 shares at an average price of $760.43 per share. After these transactions, the reported indirect holding stands at 40,976 common shares.
ARGAN INC Chief Financial Officer Joshua Scott Baugher reported option exercises and share sales in company stock. On June 17, 2026, he exercised a stock option awarded on April 16, 2024 to purchase 1,000 shares of common stock at a price of $61.22 per share using the net settle method. That same day, he sold 455 shares on the open market at $732.83 per share and 305 shares at $734 per share, resulting in total open-market sales of 760 shares.
ARGAN INC director Karen Sweeney reported an open-market sale of company stock. On June 17, 2026, she sold 300 shares of Argan common stock at a price of $705 per share. After this transaction, she directly holds 1,548 shares of Argan common stock.
ARGAN INC director Peter W. Getsinger reported an option exercise followed by open-market sales of common stock. On June 15, 2026, he exercised a stock option to purchase 5,000 shares at $35.72 per share using the net settle method, resulting in 4,728 shares of common stock.
He then sold 4,728 shares on June 16, 2026 at an average price of $708.65 per share and 2,000 additional shares on June 17, 2026 at an average price of $699.00 per share. After these transactions, he directly owns 4,880 shares of common stock and 3,000 options to purchase common stock, and indirectly reports 133 shares held in a custody account for a child and 267 shares held in a children's trust.
ARGAN INC director Cynthia Flanders reported an open-market sale of 2,596 shares of the company’s common stock. The trade took place on June 15, 2026 at a price of $666.31 per share. Following this transaction, she directly holds 23,144 common shares.
ARGAN INC president and CEO David Hibbert Watson reported a mix of stock sales and option exercises in company shares. On June 15, 2026, he sold 9,993 common shares in open-market trades at an average price of $651.22 per share. On June 16, 2026, he sold a further 1,880 shares at an average price of $707.35 per share and exercised stock options covering a total of 3,333 shares at exercise prices of $39.47, $61.22, and $148.72 per share using the net settle method. The filing reflects both profit-taking sales and increased direct ownership from option exercises.
ARGAN INC director-associated entity sells shares in an open-market transaction. On June 12, 2026, an entity associated with director William F. Griffin Jr., identified as William F Griffin Jr GRAT II dtd Oct 6, 2025, sold 50,000 shares of Argan common stock at an average price of $643.46 per share. Following this sale, the GRAT continued to hold 90,976 Argan shares indirectly for Griffin.
ARGAN INC director Cynthia Flanders reported several equity-related moves involving the company’s common stock and restricted stock units. She exercised derivative securities to acquire 533 shares of common stock, then made a bona fide gift of 1,000 common shares, leaving her with 25,207 shares held directly.
Flanders’ compensation also included equity awards tied to future service. She was granted time-based restricted stock units covering 189 shares of common stock, which will fully vest on June 10, 2027 or on the date of the 2027 Annual Meeting of Stockholders, whichever occurs first. She also converted 530 previously awarded time-based restricted stock units into common shares, and now holds 834 time-based restricted stock units following these transactions.
ARGAN INC director Karen Sweeney reported routine equity compensation transactions. On June 10, 2026, she exercised awards to acquire 533 shares of common stock, bringing her direct common stock holdings to 1,848 shares. She also converted previously granted time-based restricted stock units (TRSUs) into 530 shares of common stock that became issuable under a one-year vesting schedule tied to TRSUs awarded on June 17, 2025. In addition, she received a new grant of 189 TRSUs, each linked to one share of common stock, which will vest in full on June 10, 2027 or on the date of the 2027 Annual Meeting of Stockholders, whichever occurs first. No sales or dispositions were reported in this filing.
Leimkuhler William F. reported acquisition or exercise transactions in this Form 4 filing.
ARGAN INC director William F. Leimkuhler reported routine equity compensation activity. On June 10, 2026, 530 Time-Based Restricted Stock Units (TRSUs) vested into common shares under a one-year schedule from a June 17, 2025 award, and he was granted a new award of 189 TRSUs that will fully vest on June 10, 2027 or at the 2027 Annual Meeting of Stockholders, whichever comes first. Following these transactions, he directly holds 37,028 shares of common stock, 1,023 TRSUs, and indirectly holds 500 shares in each of two trusts for which he serves as trustee.
ARGAN INC director Jeffrey John Ronald Jr. reported compensation-related equity activity and updated holdings. On June 10, 2026, he exercised derivative awards to acquire 533 shares of common stock at $0.00 per share, bringing his direct common stock holdings to 2,533 shares.
On the same date, 530 Time-Based Restricted Stock Units (TRSUs) vested and became issuable as common stock under a one-year vesting schedule, and he received a new grant of 189 TRSUs that will fully vest on June 10, 2027 or at the 2027 Annual Meeting, whichever occurs first. He also reports 8,000 shares of common stock held indirectly through a John R. Jeffrey IRA. No open-market purchases or sales were reported.
QUINN JAMES W reported acquisition or exercise transactions in this Form 4 filing.
ARGAN INC director James W. Quinn reported equity compensation-related transactions with no open-market buying or selling. On June 10, 2026, 530 shares of common stock became issuable to him as earlier-awarded Time-Based Restricted Stock Units vested, increasing his directly held common stock to 15,580 shares.
On the same date, he received a new grant of 189 Time-Based Restricted Stock Units, which will vest fully on June 10, 2027 or on the date of the 2027 Annual Meeting of Stockholders, whichever comes first. Following these transactions, he also indirectly holds 36,223 common shares through the James W. Quinn 2025 GRAT No.1 and directly holds 1,023 Time-Based Restricted Stock Units.
Getsinger Peter W reported acquisition or exercise transactions in this Form 4 filing.
ARGAN INC director Peter W. Getsinger reported equity compensation activity involving the company’s common stock and restricted stock units. On June 10, 2026, 530 shares of common stock became issuable to him as Time-Based Restricted Stock Units (TRSUs) vested under a one-year vesting schedule.
On the same date, he was granted new TRSUs covering 189 shares of common stock, which will fully vest on June 10, 2027 or on the date of the 2027 Annual Meeting of Stockholders, whichever occurs first. Following these transactions, he holds 6,880 shares of common stock directly, plus small indirect holdings in a custody account for a child and a children’s trust, and 1,023 TRSUs directly.
ARGAN INC director Alexander Lisa Larroque reported equity compensation activity, not open-market trading. On June 10, 2026, she exercised previously granted Time-Based Restricted Stock Units, receiving 533 shares of common stock at a reported price of $0.00 per share, bringing her direct common stock holdings to 883 shares.
On the same date, she was also granted 189 Time-Based Restricted Stock Units, each representing a right to receive one share of common stock. According to the vesting terms, these TRSUs will fully vest on June 10, 2027 or on the date of the 2027 Annual Meeting of Stockholders, whichever occurs first.
ARGAN INC director Peter W. Getsinger reported multiple share movements involving the company’s common stock. On April 29, 2026, he sold 3,000 shares in an open‑market transaction at an average price of $628.36 per share, leaving 6,847 shares held directly after this sale.
On the same date, he also made a bona fide gift of 500 shares of common stock. In addition to his direct holdings, he reports indirect ownership of 133 shares held in a custody account for a child and 267 shares held in a children's trust.
ARGAN INC director Lisa Larroque Alexander sold common stock in an open-market trade. On April 29, 2026, the reporting person sold 350 shares of Argan’s common stock at an average price of $630.58 per share.
After this transaction, the director directly owned 350 shares of Argan common stock, according to the Form 4. The filing reports no derivative securities, so the activity relates only to non-derivative common stock holdings.
ARGAN INC director William F. Leimkuhler reported open-market sales of 5,800 shares of Argan common stock. On April 28, 2026, he sold 5,000 shares directly at an average price of $617.41 per share.
On the same date, the Emily K. Leimkuhler Trust and the Elizabeth K. Leimkuhler Trust, for which he serves as trustee, each sold 400 shares in open-market transactions, at reported prices of $621.14 and $618.61 per share. Following these sales, Leimkuhler holds 36,495 shares directly, and each trust holds 500 shares indirectly attributed to him as trustee.
ARGAN INC director Jeffrey John Ronald Jr. reported an open-market sale of the company’s common stock. On April 27, 2026, he sold 2,698 shares at an average price of $664.84 per share, leaving 2,000 shares held directly and 8,000 shares held indirectly through a John R. Jeffrey IRA.
ARGAN INC executive Charles Edwin Collins IV, CEO of Gemma, reported option exercises and share sales in April 2026. He exercised stock options to acquire a total of 13,568 shares of common stock at exercise prices ranging from $33.81 to $148.72 per share.
On April 20, 2026, he exercised an option for 2,500 shares at $39.47 per share and sold 2,500 shares at $610 per share. On April 21, 2026, he exercised additional options totaling 11,068 shares and sold 11,068 shares at an average price of $621.61 per share. Following these transactions, he directly holds 30,320 shares of ARGAN common stock.
ARGAN INC director Jeffrey John Ronald Jr. reported an option exercise and share sale. On April 21, 2026, he exercised a stock option for 5,000 shares of common stock at $37.13 per share using a net settle method, receiving 4,698 shares of common stock.
That same day, he sold 3,636 shares of common stock in open-market transactions at an average price of $615.40 per share. After these transactions, he held 4,698 shares directly and 8,000 shares indirectly through a John R. Jeffrey IRA.
ARGAN INC executive Charles Edwin Collins IV, CEO of Gemma, reported multiple equity award vestings and option exercises that increased his direct holdings. On April 16–17, 2026, he exercised derivative awards to acquire a total of 13,166 shares of common stock, all coded as option or unit exercises rather than open-market purchases or sales.
Following these transactions, he directly owned 30,320 shares of common stock. Footnotes explain that the vested awards include Renewable Performance-Based Restricted Stock Units, Time-Based Restricted Stock Units, Earnings Per Share Performance-Based Restricted Stock Units, and other performance-based units granted in prior years, which became issuable in 2026 under their one- and three-year vesting schedules.
ARGAN INC President and CEO David Hibbert Watson reported multiple equity award vestings and one stock sale. On April 17, 2026, he sold 19,310 shares of common stock in the open market at an average price of $602.11 per share, and held 49,998 shares directly afterward. Around the same time, several restricted stock unit awards vested, including time-based RSUs and performance-based RSUs. Footnotes state that 20,000 shares became issuable from earnings-per-share performance-based RSUs versus a 10,000-share target, and 10,000 shares became issuable from performance-based RSUs versus a 5,000-share target, indicating awards paid out above target levels.
ARGAN INC Chief Financial Officer Joshua Scott Baugher reported a mix of equity exercises and sales. On April 16 and 17, 2026, several tranches of Time-Based Restricted Stock Units vested under three-year schedules, resulting in exercises covering a total of 2,251 shares of common stock.
On April 16, 2026, he sold 600 shares of common stock in an open-market transaction at an average price of $605.60 per share, while retaining the remainder. Following these transactions, he directly holds 1,784 shares of common stock and 2,459 Time-Based Restricted Stock Units.
ARGAN INC director Lisa Larroque Alexander reported routine equity compensation activity. On April 16, 2026, 695 Time-Based Restricted Stock Units vested and were converted into 695 shares of common stock, consistent with a one-year vesting schedule for TRSUs granted on April 16, 2025.
Following these transactions, she directly holds 700 shares of common stock and 530 Time-Based Restricted Stock Units. These entries reflect compensation-related derivative exercises rather than open-market buying or selling.
ARGAN INC director William F. Leimkuhler reported an open-market sale of company shares. On April 13, 2026, he sold 8,444 shares of Common Stock at an average price of $598.49 per share. After this transaction, he directly owns 41,495 shares of ARGAN INC common stock.
Argan Inc. granted equity awards to Charles Edwin Collins IV, Chief Executive Officer of Gemma. On April 8, 2026, he received 10-year options for 332 shares of common stock at an exercise price of $588.28 per share, vesting ratably over three years starting April 8, 2027.
He was also granted 231 time-based RSUs that vest in three equal annual installments from April 8, 2027. In addition, he received performance-based RSUs with a target of 170 shares tied to three-year relative total stock return versus 12 peers, and EPS-based RSUs with a target of 2,618 shares tied to compounded EPS growth over fiscal 2027–2029.
ARGAN INC President and CEO David Hibbert Watson reported new equity awards made on April 8, 2026. He received 10-year options to purchase 415 shares of common stock at an exercise price of $588.28 per share, vesting ratably over three years starting April 8, 2027.
He was also granted 251 time-based RSUs vesting in three equal annual installments from April 8, 2027, 284 performance-based RSUs tied to three-year total shareholder return versus 12 peers, and 3,339 EPS performance-based RSUs with payouts from 0% to 200% based on multi-year earnings targets.
ARGAN INC director William F. Griffin Jr, non-executive chairman of Gemma, received a grant of 3,339 Earnings Per Share Performance-Based Restricted Stock Units on April 8, 2026. These units convert into common stock only if multi-year earnings targets are met.
The vesting depends on the sum of earnings per share for fiscal years ending January 31, 2027, 2028 and 2029, compared with target compounded EPS growth based on fiscal years ended January 31, 2024, 2025 and 2026. The eventual payout can range from 0% to 200% of the 3,339-unit target, aligning compensation with long-term EPS performance.
Argan Inc. Chief Financial Officer Joshua Scott Baugher reported receiving multiple equity awards that increase his potential ownership in the company. On April 8, 2026, he was granted a 10-year option to purchase 208 shares of common stock at an exercise price of $588.28 per share, vesting ratably over three years starting on April 8, 2027.
He was also granted 126 time-based restricted stock units that vest in three equal annual installments beginning April 8, 2027. In addition, he received performance-based restricted stock units targeting 142 shares tied to three-year total shareholder return versus 12 peer companies, and a prior grant of earnings-per-share performance-based units targeting 1,670 shares, both with payout ranges from 0% to 200% of target based on performance over their respective three-year periods.
Argan Inc. director Peter W. Getsinger reported several transactions in the company’s common stock. On April 1, 2026, he exercised stock options to acquire 6,000 shares at strike prices of $37.13 and $43.70 per share using the net settle method. On April 2, 2026, he sold 2,581 shares in open-market trades at an average price of $552.73 per share and made a bona fide gift of 1,000 shares. After these moves, he directly holds 9,847 shares and also has indirect holdings of 267 shares in a children’s trust and 133 shares in a custody account for a child.
Argan Inc. director Jeffrey John Ronald Jr. reported an open-market sale of the company’s common stock. On March 31, 2026, he sold 4,556 shares at an average price of $539.85 per share, according to the filing footnote.
After this transaction, he directly holds 3,636 shares of Argan common stock and has an additional 8,000 shares held indirectly through an IRA account listed as “John R. Jeffrey, IRA.” No derivative securities are reported as outstanding in this filing.
Argan, Inc. director John R. Jeffrey Jr. reported an open-market sale of common stock. On January 27, 2026, he sold 5,000 shares of Argan common stock at an average price of $360.78 per share. After this transaction, he held 8,192 shares directly and 8,000 shares indirectly through a John R. Jeffrey IRA.
Argan Inc. director Cynthia A. Flanders reported an open-market sale of company stock. On January 21, 2026, she sold 19,000 shares of Argan common stock at an average price of $386.70 per share. After this transaction, she directly owned 26,207 shares of Argan common stock. The filing classifies her as a director and shows that the transaction involved non-derivative securities only, with no associated options or other derivative instruments.
Argan Inc. director John R. Jeffrey Jr. reported option exercises and a share sale. On January 16, 2026, he exercised an option to purchase 10,000 shares of Argan common stock at $45.75 per share using a net settle method, resulting in 8,636 shares of common stock being acquired. On January 20, 2026, he sold 2,700 shares of Argan common stock on the open market at an average price of $380.60 per share. After these transactions, he directly owned 13,192 shares of common stock and indirectly owned 8,000 shares through a John R. Jeffrey IRA, and held 11,500 stock options following the option exercise.
Argan Inc. director William F. Leimkuhler reported a sale of company stock. On January 16, 2026, he sold 11,044 shares of Argan Inc. common stock at an average price of $379.15 per share, as shown in the Form 4 filing.
After this transaction, he beneficially owned 49,939 shares of Argan Inc. common stock in direct ownership. This filing reflects a routine insider transaction and does not by itself describe any change in the company’s operations or financial performance.
Argan Inc. director Cynthia Flanders reported multiple stock option exercises in Argan Inc. common stock. On January 13, 2026, she exercised four "Option to Purchase Common Stock" awards covering 10,000 shares at $40.15 per share, 10,000 shares at $45.75 per share, 5,000 shares at $37.13 per share, and 5,000 shares at $35.72 per share, each described as using the net settle method.
Following these exercises, her directly held common stock increased in steps to 45,207 shares. The Form 4 also shows that after the transactions she continued to hold derivative positions in options to purchase Argan common stock, including 21,500, 11,500, 6,500 and 1,500 option shares at the respective exercise prices.
Argan Inc. director William F. Leimkuhler reported two open-market sales of the company’s common stock. On January 12, 2026, he sold 2,164 shares at an average price of $318.28 per share, and on January 13, 2026, he sold 4,212 shares at an average price of $320.53 per share, for a total of 6,376 shares sold.
After these transactions, Leimkuhler directly beneficially owned 60,983 shares of Argan common stock. The filing classifies him as a director and indicates the form is filed by one reporting person.
Argan Inc. director Peter W. Getsinger reported multiple stock transactions in early January 2026. On January 7, 2026, he sold 4,000 shares of Argan common stock on the open market at an average price of $328.34 per share. That same day, he exercised a stock option to purchase 7,500 shares at an exercise price of $40.15 per share using the net settle method, resulting in 6,595 shares of common stock being acquired.
On January 8, 2026, Getsinger sold another 6,595 shares on the open market at an average price of $313.71 per share. Following these transactions, he directly owned 7,847 shares of Argan common stock and held 14,000 stock options to purchase additional shares.
Argan Inc. director William F. Leimkuhler reported multiple stock option exercises in the company’s common stock. On January 7, 2026, he exercised options granted between December 2019 and December 2022 to purchase blocks of 10,000 and 5,000 shares at exercise prices of $40.15, $45.75, $37.13, and $35.72 per share, using the net settle method. These exercises increased his directly held common stock, and following the reported transactions he directly owned 67,359 Argan shares.
Argan Inc. director William F. Leimkuhler reported several transactions in the company’s common stock on December 23, 2025. As trustee of the Emily K. Leimkuhler Trust, he sold 100 shares at $337.01 per share in an open-market trade. As trustee of the Elizabeth K. Leimkuhler Trust, he sold another 100 shares at $337.93 per share.
On the same date, he also made a bona fide gift of 500 shares of Argan common stock. After these transactions, the filing shows 900 shares held indirectly for each of the two trusts and 41,034 shares held directly.
Argan Inc. director Peter W. Getsinger reported a bona fide gift of 750 shares of the company’s common stock. The transaction took place on December 23, 2025 and is reported on a Form 4 as a code "G" transaction, which indicates a gift. The reported transaction price is $0, consistent with a non-sale transfer.
Following this gift, the reporting person beneficially owns 11,847 shares of Argan Inc. common stock in direct ownership form. This filing simply updates the insider’s reported holdings and does not reflect an open‑market purchase or sale.
Argan, Inc. director John R. Jeffrey, Jr. reported equity compensation activity involving time-based restricted stock units that converted into common stock. On 12/14/2025, 856 shares of common stock were acquired at $0 per share, bringing his directly held stake to 5,412 shares. On 12/16/2025, he acquired a further 1,844 common shares at $0, increasing his direct holdings to 7,256 shares. Footnotes explain that these issuances came from three-year time-based restricted stock unit awards granted on 12/14/2023 and 12/16/2022, with share amounts adjusted for dividends. The filing also shows 8,000 common shares held indirectly through a John R. Jeffrey, IRA, and remaining time-based restricted stock units listed as derivative securities.
Argan Inc. director James W. Quinn reported the vesting and settlement of time-based restricted stock units into common shares. On December 14, 2025, 856 common shares were acquired at an exercise price of $0, increasing his direct holdings to 5,434 shares. On December 16, 2025, he acquired a further 1,844 shares at $0, bringing his direct ownership to 7,278 shares.
The underlying awards were Time-Based Restricted Stock Units awarded on December 14, 2023 and December 16, 2022, each with a three-year vesting schedule. According to the disclosure, 833 and 1,750 shares of common stock became issuable on December 14 and December 16, 2025, respectively, with amounts adjusted for dividends. Following these transactions, Quinn also reported indirect ownership of 43,992 shares held by the James W. Quinn 2025 GRAT No.1 and continued holdings of 3,114 and 1,364 Time-Based Restricted Stock Units.
Argan Inc director Peter W. Getsinger reported that time-based restricted stock unit awards vested and converted into common stock in two transactions during December 2025.
The awards, originally granted in December 2022 and December 2023, followed three-year vesting schedules, after which shares of Argan common stock became issuable to him at an exercise price of $0.
After these transactions, he directly owned 12,597 shares of common stock and held 1,364 time-based restricted stock units as ongoing stock-based compensation.
Argan Inc. director reports vested equity awards. On 12/14/2025 and 12/16/2025, the reporting person acquired 856 and 1,844 shares of Argan Inc. common stock at a price of $0 following the exercise of derivative awards, bringing direct ownership to 19,128 common shares.
The transactions relate to time-based restricted stock units awarded on 12/14/2023 and 12/16/2022, under which 833 and 1,750 shares of common stock became issuable on the respective 2025 vesting dates, adjusted for dividends. After these settlements, the director continues to hold 3,114 and 1,364 time-based restricted stock units as derivative securities.
Argan Inc. director William F. Leimkuhler reported stock awards vesting that increased his direct ownership of the company’s common shares. On December 14, 2025, 856 shares of common stock were acquired at $0 per share following the vesting of time-based restricted stock units awarded earlier. On December 16, 2025, a further 1,844 shares were acquired at $0 per share from another time-based restricted stock unit award.
After these transactions, Leimkuhler directly beneficially owned 41,534 shares of Argan Inc. common stock. He also continues to hold time-based restricted stock units, with 3,114 units remaining from the 2023 award and 1,364 units remaining from the 2022 award.
Argan Inc. director James W. Quinn reported recent gifts and sales of company stock. On December 9, 2025, he gifted 1,000 shares of Argan common stock to The Quinn Family Fund, a donor-advised fund, at a reported price of $0 per share. Following that transaction, he directly held 4,578 shares and The Quinn Family Fund held 1,000 shares indirectly attributed to him.
On December 10, 2025, The Quinn Family Fund sold its 1,000 shares of Argan common stock on the open market at $328.04 per share, leaving it with 0 shares. The filing also reports an additional 43,992 shares of Argan common stock held indirectly through the James W. Quinn 2025 GRAT No.1.